The global Drug based on CAR T-Cell Market growth is projected to reach US$ 430 million in 2025 to US$ 655 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.

Global Drug based on CAR T-Cell Market Growth And Outlook 2025-31

The global Drug based on CAR T-Cell market size is predicted to grow from US$ 430 million in 2025 to US$ 655 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the ?Drug based on CAR T-Cell Industry Forecast? looks at past sales and reviews total world Drug based on CAR T-Cell sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug based on CAR T-Cell sales for 2025 through 2031. With Drug based on CAR T-Cell sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug based on CAR T-Cell industry. This Insight Report provides a comprehensive analysis of the global Drug based on CAR T-Cell landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug based on CAR T-Cell portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Drug based on CAR T-Cell market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug based on CAR T-Cell and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug based on CAR T-Cell. This report presents a comprehensive overview, market shares, and growth opportunities of Drug based on CAR T-Cell market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; CD19-targeted &nbsp;&nbsp;&nbsp; BCMA-targeted Segmentation by Application: &nbsp;&nbsp;&nbsp; Lymphoma &nbsp;&nbsp;&nbsp; Multiple Myeloma This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; J & J &nbsp;&nbsp;&nbsp; JW Therapeutics &nbsp;&nbsp;&nbsp; FOSUNKite &nbsp;&nbsp;&nbsp; CARsgen Therapeutics (Pipeline) &nbsp;&nbsp;&nbsp; CARsgen Therapeutics &nbsp;&nbsp;&nbsp; Autolus Therapeutics &nbsp;&nbsp;&nbsp; Sorrento Therapeutics &nbsp;&nbsp;&nbsp; Mustang Bio &nbsp;&nbsp;&nbsp; Bluebird Bio &nbsp;&nbsp;&nbsp; Cellectis &nbsp;&nbsp;&nbsp; Allogene Therapeutics &nbsp;&nbsp;&nbsp; Celyad

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Drug based on CAR T-Cell Market Size (2020-2031) &nbsp;2.1.2 Drug based on CAR T-Cell Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Drug based on CAR T-Cell by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Drug based on CAR T-Cell Segment by Type &nbsp;2.2.1 CD19-targeted &nbsp;2.2.2 BCMA-targeted &nbsp;2.3 Drug based on CAR T-Cell Market Size by Type &nbsp;2.3.1 Drug based on CAR T-Cell Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Drug based on CAR T-Cell Market Size Market Share by Type (2020-2025) &nbsp;2.4 Drug based on CAR T-Cell Segment by Application &nbsp;2.4.1 Lymphoma &nbsp;2.4.2 Multiple Myeloma &nbsp;2.5 Drug based on CAR T-Cell Market Size by Application &nbsp;2.5.1 Drug based on CAR T-Cell Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Drug based on CAR T-Cell Market Size Market Share by Application (2020-2025) 3 Drug based on CAR T-Cell Market Size by Player &nbsp;3.1 Drug based on CAR T-Cell Market Size Market Share by Player &nbsp;3.1.1 Global Drug based on CAR T-Cell Revenue by Player (2020-2025) &nbsp;3.1.2 Global Drug based on CAR T-Cell Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Drug based on CAR T-Cell Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Drug based on CAR T-Cell by Region &nbsp;4.1 Drug based on CAR T-Cell Market Size by Region (2020-2025) &nbsp;4.2 Global Drug based on CAR T-Cell Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Drug based on CAR T-Cell Market Size Growth (2020-2025) &nbsp;4.4 APAC Drug based on CAR T-Cell Market Size Growth (2020-2025) &nbsp;4.5 Europe Drug based on CAR T-Cell Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Drug based on CAR T-Cell Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Drug based on CAR T-Cell Market Size by Country (2020-2025) &nbsp;5.2 Americas Drug based on CAR T-Cell Market Size by Type (2020-2025) &nbsp;5.3 Americas Drug based on CAR T-Cell Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Drug based on CAR T-Cell Market Size by Region (2020-2025) &nbsp;6.2 APAC Drug based on CAR T-Cell Market Size by Type (2020-2025) &nbsp;6.3 APAC Drug based on CAR T-Cell Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Drug based on CAR T-Cell Market Size by Country (2020-2025) &nbsp;7.2 Europe Drug based on CAR T-Cell Market Size by Type (2020-2025) &nbsp;7.3 Europe Drug based on CAR T-Cell Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Drug based on CAR T-Cell by Region (2020-2025) &nbsp;8.2 Middle East & Africa Drug based on CAR T-Cell Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Drug based on CAR T-Cell Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Drug based on CAR T-Cell Market Forecast &nbsp;10.1 Global Drug based on CAR T-Cell Forecast by Region (2026-2031) &nbsp;10.1.1 Global Drug based on CAR T-Cell Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Drug based on CAR T-Cell Forecast &nbsp;10.1.3 APAC Drug based on CAR T-Cell Forecast &nbsp;10.1.4 Europe Drug based on CAR T-Cell Forecast &nbsp;10.1.5 Middle East & Africa Drug based on CAR T-Cell Forecast &nbsp;10.2 Americas Drug based on CAR T-Cell Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Drug based on CAR T-Cell Forecast &nbsp;10.2.2 Canada Market Drug based on CAR T-Cell Forecast &nbsp;10.2.3 Mexico Market Drug based on CAR T-Cell Forecast &nbsp;10.2.4 Brazil Market Drug based on CAR T-Cell Forecast &nbsp;10.3 APAC Drug based on CAR T-Cell Forecast by Region (2026-2031) &nbsp;10.3.1 China Drug based on CAR T-Cell Market Forecast &nbsp;10.3.2 Japan Market Drug based on CAR T-Cell Forecast &nbsp;10.3.3 Korea Market Drug based on CAR T-Cell Forecast &nbsp;10.3.4 Southeast Asia Market Drug based on CAR T-Cell Forecast &nbsp;10.3.5 India Market Drug based on CAR T-Cell Forecast &nbsp;10.3.6 Australia Market Drug based on CAR T-Cell Forecast &nbsp;10.4 Europe Drug based on CAR T-Cell Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Drug based on CAR T-Cell Forecast &nbsp;10.4.2 France Market Drug based on CAR T-Cell Forecast &nbsp;10.4.3 UK Market Drug based on CAR T-Cell Forecast &nbsp;10.4.4 Italy Market Drug based on CAR T-Cell Forecast &nbsp;10.4.5 Russia Market Drug based on CAR T-Cell Forecast &nbsp;10.5 Middle East & Africa Drug based on CAR T-Cell Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Drug based on CAR T-Cell Forecast &nbsp;10.5.2 South Africa Market Drug based on CAR T-Cell Forecast &nbsp;10.5.3 Israel Market Drug based on CAR T-Cell Forecast &nbsp;10.5.4 Turkey Market Drug based on CAR T-Cell Forecast &nbsp;10.6 Global Drug based on CAR T-Cell Forecast by Type (2026-2031) &nbsp;10.7 Global Drug based on CAR T-Cell Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Drug based on CAR T-Cell Forecast 11 Key Players Analysis &nbsp;11.1 Novartis &nbsp;11.1.1 Novartis Company Information &nbsp;11.1.2 Novartis Drug based on CAR T-Cell Product Offered &nbsp;11.1.3 Novartis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Novartis Main Business Overview &nbsp;11.1.5 Novartis Latest Developments &nbsp;11.2 Gilead Sciences &nbsp;11.2.1 Gilead Sciences Company Information &nbsp;11.2.2 Gilead Sciences Drug based on CAR T-Cell Product Offered &nbsp;11.2.3 Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Gilead Sciences Main Business Overview &nbsp;11.2.5 Gilead Sciences Latest Developments &nbsp;11.3 Bristol-Myers Squibb &nbsp;11.3.1 Bristol-Myers Squibb Company Information &nbsp;11.3.2 Bristol-Myers Squibb Drug based on CAR T-Cell Product Offered &nbsp;11.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.3.5 Bristol-Myers Squibb Latest Developments &nbsp;11.4 J & J &nbsp;11.4.1 J & J Company Information &nbsp;11.4.2 J & J Drug based on CAR T-Cell Product Offered &nbsp;11.4.3 J & J Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 J & J Main Business Overview &nbsp;11.4.5 J & J Latest Developments &nbsp;11.5 JW Therapeutics &nbsp;11.5.1 JW Therapeutics Company Information &nbsp;11.5.2 JW Therapeutics Drug based on CAR T-Cell Product Offered &nbsp;11.5.3 JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 JW Therapeutics Main Business Overview &nbsp;11.5.5 JW Therapeutics Latest Developments &nbsp;11.6 FOSUNKite &nbsp;11.6.1 FOSUNKite Company Information &nbsp;11.6.2 FOSUNKite Drug based on CAR T-Cell Product Offered &nbsp;11.6.3 FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 FOSUNKite Main Business Overview &nbsp;11.6.5 FOSUNKite Latest Developments &nbsp;11.7 CARsgen Therapeutics (Pipeline) &nbsp;11.7.1 CARsgen Therapeutics (Pipeline) Company Information &nbsp;11.7.2 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product Offered &nbsp;11.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 CARsgen Therapeutics (Pipeline) Main Business Overview &nbsp;11.7.5 CARsgen Therapeutics (Pipeline) Latest Developments &nbsp;11.8 CARsgen Therapeutics &nbsp;11.8.1 CARsgen Therapeutics Company Information &nbsp;11.8.2 CARsgen Therapeutics Drug based on CAR T-Cell Product Offered &nbsp;11.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 CARsgen Therapeutics Main Business Overview &nbsp;11.8.5 CARsgen Therapeutics Latest Developments &nbsp;11.9 Autolus Therapeutics &nbsp;11.9.1 Autolus Therapeutics Company Information &nbsp;11.9.2 Autolus Therapeutics Drug based on CAR T-Cell Product Offered &nbsp;11.9.3 Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Autolus Therapeutics Main Business Overview &nbsp;11.9.5 Autolus Therapeutics Latest Developments &nbsp;11.10 Sorrento Therapeutics &nbsp;11.10.1 Sorrento Therapeutics Company Information &nbsp;11.10.2 Sorrento Therapeutics Drug based on CAR T-Cell Product Offered &nbsp;11.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Sorrento Therapeutics Main Business Overview &nbsp;11.10.5 Sorrento Therapeutics Latest Developments &nbsp;11.11 Mustang Bio &nbsp;11.11.1 Mustang Bio Company Information &nbsp;11.11.2 Mustang Bio Drug based on CAR T-Cell Product Offered &nbsp;11.11.3 Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Mustang Bio Main Business Overview &nbsp;11.11.5 Mustang Bio Latest Developments &nbsp;11.12 Bluebird Bio &nbsp;11.12.1 Bluebird Bio Company Information &nbsp;11.12.2 Bluebird Bio Drug based on CAR T-Cell Product Offered &nbsp;11.12.3 Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Bluebird Bio Main Business Overview &nbsp;11.12.5 Bluebird Bio Latest Developments &nbsp;11.13 Cellectis &nbsp;11.13.1 Cellectis Company Information &nbsp;11.13.2 Cellectis Drug based on CAR T-Cell Product Offered &nbsp;11.13.3 Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 Cellectis Main Business Overview &nbsp;11.13.5 Cellectis Latest Developments &nbsp;11.14 Allogene Therapeutics &nbsp;11.14.1 Allogene Therapeutics Company Information &nbsp;11.14.2 Allogene Therapeutics Drug based on CAR T-Cell Product Offered &nbsp;11.14.3 Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Allogene Therapeutics Main Business Overview &nbsp;11.14.5 Allogene Therapeutics Latest Developments &nbsp;11.15 Celyad &nbsp;11.15.1 Celyad Company Information &nbsp;11.15.2 Celyad Drug based on CAR T-Cell Product Offered &nbsp;11.15.3 Celyad Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.15.4 Celyad Main Business Overview &nbsp;11.15.5 Celyad Latest Developments 12 Research Findings and Conclusion

Report	Global Drug based on CAR T-Cell Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI9765

Buyer Information

Order Summary